Ibrutinib Improves Outcomes in CLL/SLL

News
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video examines a phase III trial of ibrutinib in combination with bendamustine and rituximab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.

In this video, Asher A. Chanan-Khan, MD, of the Mayo Clinic in Jacksonville, Florida, discusses a phase III trial of ibrutinib in combination with bendamustine and rituximab in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

The trial’s results (abstract LBA7005) were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held May 29–June 2 in Chicago.

Recent Videos
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content
Cellular therapies are a treatment modality that hold promise in various cancer types.

Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types

Tim Cortese
August 8th 2025
Article

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Durable Response to CAR T is Associated With Elevated Activation and Clonotypic Expansion of the Cytotoxic Native T Cell Repertoire

Durable Response to CAR T is Associated With Elevated Activation and Clonotypic Expansion of the Cytotoxic Native T Cell Repertoire

American Society for Transplantation and Cellular Therapy
July 30th 2025
Article

Researchers have identified the transcription factor CEBPA as a crucial regulator of immune recognition in acute myeloid leukemia.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL.

Pirtobrutinib Yields Noninferior ORR Vs Ibrutinib in CLL/SLL

Russ Conroy
July 30th 2025
Article

Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL.

AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.

sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL

Roman Fabbricatore
July 29th 2025
Article

AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.